Jeffrey V. Lazarus (PhD, MIH, MA) is a Professor of Global Health at the City University of New York Graduate School of Public Health and Policy. He also holds positions as a research professor at the Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, where he leads the health systems research team, and as an affiliated professor at the University of Copenhagen WHO collaborating centre on patient perspectives on medicine.

His decade-long career as health systems, HIV, and viral hepatitis expert at WHO Europe was followed by three years (2009-2012) as a senior specialist at the Global Fund to Fight AIDS, Tuberculosis, and Malaria, three years as director of Health Systems Global (2012-15) then board chair of the foundation AFEW International (2015-18).

Prof Lazarus is the chair of the Healthy Livers, Health Lives coalition, formed by AASLD, ALEH, APASL. EASL and SOLDA and he is on the leadership committee of the Global NASH Council. He is the Principal Investigator (PI) of 10 active projects and trials and is the author of more than 400 publications.

His work includes leading the NAFLD public health consensus statement (Nature Reviews GastroHep 2021), the new fatty liver disease nomenclature, published in 3 society journals (2023), the global research (J Hepatology 2023) and action priorities (Hepatology 2023), the expert recommendation on NAFLD models of care (Nature Reviews GastroHep 2021), the fatty liver disease-Sustainable Development Goals score (Hepatology 2023), and the Global COVID-19 Consensus Statement (Nature 2022), and he is a co-author of the EASL NAFLD patient guideline (JHEP Reports 2021) and the Lancet GastroHep Commission on Viral Hepatitis (2024).

He is on the editorial board of the Journal of Hepatology and Liver International. In 2023, he co-chaired the EASL SLD Summit and the Liver Connect NAFLD Summit. In 2017, he was a recipient of The Economist Intelligence Unit Change Maker award, given in recognition of significant contributions to the global elimination of hepatitis C, and in 2023 the American Liver Foundation Distinguished Scientific Achievement award.

Dr. George is an Advanced Accredited Practicing Dietitian and Senior Research Fellow in Nutrition and Dietetics at Deakin University’s Institute for Physical Activity and Nutrition (IPAN). Ranked among the top 0.6% of researchers globally and the #1 Australian Dietitian in fatty liver disease, she is also in the top 2% worldwide for nutrition therapy and the Mediterranean diet. Her research focuses on the practical application of dietary patterns for preventing and managing chronic diseases such as metabolic liver disease, diabetes, and cardiovascular disease.

With over 10 years of experience in clinical research and private practice, Dr. George’s work emphasizes translating research into practice, especially through evidence-based lifestyle management. She also aims to address healthcare workforce limitations by developing simple, protocolized dietary interventions that can be implemented by other professionals. Her internationally recognized research includes sociocultural adaptations of diets for multicultural groups, pioneering improved dietary interventions for chronic disease prevention and management.

Professor Adams (MBBS, FRACP, PhD) is a Consultant Hepatologist at Sir Charles Gairdner Hospital and lead of the Liver Research Group in the Medical School, University of Western Australia (UWA).  His research interests focus on clinical and translational aspects of MAFLD and non-invasive assessment of liver disease where he has >200 research publications.

He is currently leading two national MRFF funded clinical trials to optimize the detection of advanced liver disease in primary care. He is chair of the GESA consensus steering committee for the assessment of fatty liver disease in primary care, and has served on numerous journal editorial boards, faculties and committees within GESA, the Australian Diabetes Society, Cancer Council Australia, the American Gastroenterology Association and American Association for the Study of Liver Disease.

Associate Professor Paul Gow has spent the last 30 years involved in various aspects of liver health and disease, as a Gastroenterologist and Liver Transplant Specialist at the Austin Hospital and in private practice. He investigates and treats all gastroenterological disorders and has particular interest in liver disease (viral hepatitis, fatty liver disease and auto-immune liver diseases).

Paul has published over 170 peer-reviewed research articles and supervised numerous PhD projects. He authored the book Liver Better Life, which debunks misconceptions about liver health and offers practical advice. Paul is dedicated to excellence in patient-centered care.

Elaine Montegriffo is CEO of LiverWELL. A visionary, purposeful leader with extensive senior executive leadership and board governance experience across sectors and cultures, and a passion for collaborating to create a better world. Elaine has held executive leadership roles with Oxfam and Australian Red Cross and is a passionate advocate for equitable access to human rights, especially healthcare. Elaine serves on the Victorian Board of the Medical Board of Australia and on the Board of GenWest, supporting multicultural communities in the west of Melbourne to live safe, healthy lives.